Skip to main content Skip to navigation
Antibody Cocktail (TNF-α FITC, CD69 PE, CD4 PerCP-Cy™5.5, CD3 APC)

Antibody Cocktail (TNF-α FITC, CD69 PE, CD4 PerCP-Cy™5.5, CD3 APC)

(RUO (GMP))
Product Details
Down Arrow Up Arrow


BD FastImmune™
Human
Flow cytometry
RUO (GMP)
Phosphate buffered saline with BSA, beta-lactoglobulin, and 0.1% sodium azide.


Description

Anti-Hu–TNF-α, clone 6401.1111, is derived from a fusion of Sp2/0 myeloma cells with splenocytes from BALB/c mice immunized with recombinant human TNF-α.

CD69, clone L78, is derived from hybridization of mouse Sp2/0-Ag14 myeloma cells with lymph node cells from BALB/c mice immunized with a CD8+ alloantigen-directed cytotoxic T-lymphocyte (CTL) cell line.

CD4, clone SK3, is derived from hybridization of mouse NS-1 myeloma cells with spleen cells from BALB/c mice immununized with human peripheral blood T lymphocytes.

CD3, clone SK7, is derived from hybridization of mouse NS-1 myeloma cells with spleen cells from BALB/c mice immunized with human thymocytes.

Anti-Human Tumor Necrosis Factor-α (Anti-Hu–TNF-α) recognizes a 26-kilodalton (kd) transmembrane protein.

CD69 recognizes a very early human activation antigen. The CD69 antigen is a surface homodimer formed by the association of 28-kd and 32-kd chains that are held together by disulfide bridges.

The CD4 antigen, Mr 55 kd, is present on T-helper/inducer lymphocytes and monocytes.

CD3 reacts with the epsilon chain of the CD3 antigen/T-cell antigen receptor (TCR) complex. This complex is composed of at least six proteins that range in molecular weight from 20 to 30 kd. The antigen recognized by CD3 antibodies is noncovalently associated with either α/β or γ/δ TCR (70 to 90 kd).


Anti-Hu–TNF-α, clone 6401.1111, is derived from a fusion of Sp2/0 myeloma cells with splenocytes from BALB/c mice immunized with recombinant human TNF-α.

CD69, clone L78, is derived from hybridization of mouse Sp2/0-Ag14 myeloma cells with lymph node cells from BALB/c mice immunized with a CD8+ alloantigen-directed cytotoxic T-lymphocyte (CTL) cell line.

CD4, clone SK3, is derived from hybridization of mouse NS-1 myeloma cells with spleen cells from BALB/c mice immununized with human peripheral blood T lymphocytes.

CD3, clone SK7, is derived from hybridization of mouse NS-1 myeloma cells with spleen cells from BALB/c mice immunized with human thymocytes.

Anti-Human Tumor Necrosis Factor-α (Anti-Hu–TNF-α) recognizes a 26-kilodalton (kd) transmembrane protein.

CD69 recognizes a very early human activation antigen. The CD69 antigen is a surface homodimer formed by the association of 28-kd and 32-kd chains that are held together by disulfide bridges.

The CD4 antigen, Mr 55 kd, is present on T-helper/inducer lymphocytes and monocytes.

CD3 reacts with the epsilon chain of the CD3 antigen/T-cell antigen receptor (TCR) complex. This complex is composed of at least six proteins that range in molecular weight from 20 to 30 kd. The antigen recognized by CD3 antibodies is noncovalently associated with either α/β or γ/δ TCR (70 to 90 kd).

Preparation And Storage

Store vials at 2°C–8°C. Conjugated forms should not be frozen. Protect from exposure to light. Each reagent is stable until the expiration date shown on the bottle label when stored as directed.

337190 Rev. 1
Components
Down Arrow Up Arrow
Description Clone Isotype EntrezGene ID
CD3 APC SK7 IgG1, κ N/A
TNF FITC 6401.1111 IgG1, N/A
CD69 PE 2D7/Basophils IgG1, κ N/A
CD4 PerCP-CY5.5 SK3 IgG1, κ N/A
337190 Rev. 1
Citations & References
Down Arrow Up Arrow

Development References (51)

  1. Asanuma H, Sharp M, Maecker HT, Maino VC, Arvin AM. Frequencies of memory T cells specific for varicella-zoster virus, herpes simplex virus, and cytomegalovirus determined by intracellular detection of cytokine expression. J Infec Dis. 2000; 181:859-866. (Biology).
  2. Aversa G, Punnonen J, de Vries JE. The 26-kD transmembrane form of tumor necrosis factor α on activated CD4+ T cell clones provides a co-stimulatory signal for human B cell activation. J Exp Med. 1993; 177:1575-1585. (Biology).
  3. Bernard A, Boumsell L, Hill C. Joint report of the first international workshop on human leucocyte differentiation antigens by the investigators of the participating laboratories. In: Bernard A, Boumsell L, Dausset J, Milstein C, Schlossman SF, ed. Leucocyte Typing. New York, NY: Springer-Verlag; 1984:9-108.
  4. Beutler B, Cerami A. CachectMore than a tumor necrosis factor. N Eng J Med. 1987; 316:379-385. (Biology).
  5. Beutler B, Cerami A. Tumor necrosis, cachexia, shock, and inflammation: a common mediator. Ann Rev Biochem. 1988; 57:505-518. (Biology).
  6. Brenner M, Groh V, Porcelli A, et al. Knapp W, Dörken B, Gilks W, et al, ed. Leucocyte Typing IV: White Cell Differentiation Antigens. 1989:1049-1053.
  7. Centers for Disease Control. Perspectives in disease prevention and health promotion update: universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other bloodborne pathogens in health-care settings. MMWR. 1988; 37:377-388. (Biology).
  8. Chen JH, Prince H, Buck D, et al. Leu-23: an early activation antigen on human lymphocytes. Fed Proc. 1988; 2:A1214. (Biology).
  9. Clevers H, Alarcón B, Wileman T, Terhorst C. The T cell receptor/CD3 complex: a dynamic protein ensemble. Annual Rev Immunol. 1988; 6:629. (Biology).
  10. Clinical and Laboratory Standards Institute. 2005. (Biology).
  11. Cuturi MC, Murphy M, Costa-Giomi P, et al. Independent regulation of tumor necrosis factor and lymphotoxin production by human peripheral blood lymphocytes. J Exp Med. 1987; 165:1581-1594. (Biology).
  12. Dalgleish AG, Beverley PC, Clapham PR, Crawford DH, Greaves MF, Weiss RA. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus.. Nature. 312(5996):763-7. (Biology). View Reference
  13. Engleman EG, Benike CJ, Glickman E, Evans RL. Antibodies to membrane structures that distinguish suppressor/cytotoxic and helper T lymphocyte subpopulations block the mixed leukocyte reaction in man. J Exp Med. 1981; 154(1):193-198. (Biology). View Reference
  14. Evans RL, Wall DW, Platsoucas CD, et al. Thymus-dependent membrane antigens in man: inhibition of cell-mediated lympholysis by monoclonal antibodies to TH2 antigen. Proc Natl Acad Sci U S A. 1981; 78(1):544-548. (Biology). View Reference
  15. Grell M, Douni E, Wajant H, et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80-kDa tumor necrosis receptor. Cell. 1995; 83:793-802. (Biology).
  16. Hsu H, Shu HB, Pan MG, Goeddel DV. TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell. 1996; 84(2):299-308. (Biology). View Reference
  17. Jones EY, Stuart DI, Walker NPC. Structure of tumour necrosis factor. Nature. 1989; 338:225-228. (Biology).
  18. Kinkhabwala M Sehajpal P, Skolnik E, et al. A novel addition to the T cell repertory, Cell surface expression of tumor necrosis factor/cachectin by activated normal human T cells. J Exp Med. 1990; 171:941-946. (Biology).
  19. Komanduri KV, Viswanathan MN, Wieder ED, et al. Restoration of cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1. Nat Med. 1998; 4:953-956. (Biology).
  20. Kotzin BL, Benike CJ, Engleman EG. Induction of immunoglobulin-secreting cells in the allogeneic mixed leukocyte reaction: regulation by helper and suppressor lymphocyte subsets in man. J Immunol. 1981; 127(9):931-935. (Biology). View Reference
  21. Kriegler M, Perez C, DeFay K, Albert I, Lu SD. A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF. Cell. 1988; 53(1):45-53. (Biology). View Reference
  22. Lanier LL, Buck DW, Rhodes L, et al. Interleukin 2 activation of natural killer cells rapidly induces the expression and phosphorylation of the Leu-23 activation antigen.. J Exp Med. 1988; 167(5):1572-85. (Biology). View Reference
  23. Ledbetter JA, Evans RL, Lipinski M, Cunningham-Rundles C, Good RA, Herzenberg LA. Evolutionary conservation of surface molecules that distinguish T lymphocyte helper/inducer and cytotoxic/suppressor subpopulations in mouse and man. J Exp Med. 1981; 153(2):310-323. (Biology). View Reference
  24. Lee PP, Yee C, Savage PA, et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Ned. 1999; 5:677-685. (Biology).
  25. Lewis DE, Puck JM, Babcock GF, Rich RR. Disproportionate expansion of a minor T cell subset in patients with lymphadenopathy syndrome and acquired immunodeficiency syndrome.. J Infect Dis. 1985; 151(3):555-9. (Biology). View Reference
  26. Luettig B, Decker T, Lohmann-Matthes M-L. Evidence for the existence of two forms of membrane tumor necrosis factor: An integral protein and a molecule attached to its receptor. J Immunol. 1989; 143:4034-4038. (Biology).
  27. Michie HR, Manogue KR, Spriggs DR, et al. Detection of circulating tumor necrosis factor after endotoxin administration. N Eng J Med. 1988; 318:1481-1486. (Biology).
  28. Nomura LE, Walker JM, Maecker HT. Optimization of whole blood antigen-specific cytokine assays for CD4+ T cells. Cytometry. 2000; 40:60-68. (Biology).
  29. Ohno T, Kanoh T, Suzuki T, et al. Comparative analysis of lymphocyte phenotypes between carriers of human immunodeficiency virus (HIV) and adult patients with primary immunodeficiency using two-color immunofluorescence flow cytometry.. Tohoku J Exp Med. 1988; 154(2):157-72. (Biology). View Reference
  30. Old LJ. Tumor necrosis factor (TNF). Science. 1985; 230:630-632. (Biology).
  31. Pitcher CJ, Quittner C, Peterson DM, et al. HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression.. Nat Med. 1999; 5(5):518-25. (Biology). View Reference
  32. Reichert T, DeBruyere M, Deneys V, et al. Lymphocyte subset reference ranges in adult Caucasians. Clin Immunol Immunopathol. 1991; 60(2):190-208. (Biology). View Reference
  33. Santis AG, Campanero MR, Alonso JL, et al. Tumor necrosis factor-α production induced in T lymphocytes through the AIM/CD69 activation pathway. Eur J Immunol. 1992; 22:1253-1259. (Biology).
  34. Sattentau QJ, Dalgleish AG, Weiss RA, Beverley PC. Epitopes of the CD4 antigen and HIV infection. Science. 1986; 234(4780):1120-1123. (Biology). View Reference
  35. Schwarting R, Biedobitek G, Stein H. Knapp W, Dörken B, Gilks WR, et al, ed. Leucocyte Typing IV: White Cell Differentiation Antigens. New York, NY: Oxford University Press; 1989:428-432.
  36. Smith CA, Farrah T, Goodwin RG. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell. 1994; 76(6):959-962. (Biology). View Reference
  37. Stites DP, Casavant CH, McHugh TM, et al. Flow cytometric analysis of lymphocyte phenotypes in AIDS using monoclonal antibodies and simultaneous dual immunofluorescence.. Clin Immunol Immunopathol. 1986; 38(2):161-77. (Biology). View Reference
  38. Sung SJ, Bjorndahl JM, Wang CY, et al. Production of tumor necrosis factor/cachectin by human B cell lines and tonsillar B cells. J Exp Med. 1988; 168:1539-1551. (Biology).
  39. Sung SJ, Jung LKL, Walters JA, et al. Production of tumor necrosis factor/cachectin by human B cell lines and tonsillar B cells. J Exp Med. 1988; 167:937-953. (Biology).
  40. Suni MA, Picker LJ, Maino VC. Detection of antigen-specific T cell cytokine expression in whole blood by flow cytometry.. J Immunol Methods. 1998; 212(1):89-98. (Biology). View Reference
  41. Tartaglia LA, Goeddel DV, Reynolds C, et al. Stimulation of human T-cell proliferation by specific activation of the 75-kDa tumor necrosis factor receptor. J Immunol. 1993; 151:4637-4641. (Biology).
  42. Tartaglia LA, Goeddel DV. Two TNF receptors. Immunol Today. 1992; 13:151-153. (Biology).
  43. Testi R, Philips J, Lanier LL. Constitutive expression of a phosphorylated activation (Leu-23) by CD3 bright thymocytes. J Immunol. 1988; 141:2257. (Biology).
  44. Testi R, Philips JH, Lanier LL. Leu-23 induction as an early marker for functional CD3/T cell antigen receptor triggering: requirement for receptor cross-linking, prolonged elevation of intracellular (Ca ++ ), and stimulation of protein kinase C. J Immunol. 1988; 2:1214. (Biology).
  45. Testi R, Phillips JH, Lanier LL. T cell activation via Leu-23 (CD69).. J Immunol. 1989; 143(4):1123-8. (Biology). View Reference
  46. Testi R, Pulcinelli F, Frati L, Gazzaniga PP, Santoni A. CD69 is expressed on platelets and mediates platelet activation and aggregation.. J Exp Med. 1990; 172(3):701-7. (Biology). View Reference
  47. Thompson CB, Lindsten T, Ledbetter JA, et al. CD28 activation pathway regulates the production of multiple T-cell–derived lymphokines/cytokines. Proc Natl Acad Sci USA. 1989; 86:1333-1337. (Biology).
  48. Waldrop S, Pitcher C, Peterson D, Maino V, Picker L. Determination of antigen-specific memory/effector CD4 T cell frequencies by flow cytometry. J Clin Invest. 1997; 99:1739-1750. (Biology).
  49. Waldrop SL, Davis KA, Maino VC, Picker LJ. Normal human CD4+ memory T cells display broad heterogeneity in their activation threshold for cytokine synthesis.. J Immunol. 1998; 161(10):5284-95. (Biology). View Reference
  50. Wood GS, Warner NL, Warnke RA. Anti–Leu-3/T4 antibodies react with cells of monocyte/macrophage and Langerhans lineage. J Immunol. 1983; 131(1):212-216. (Biology). View Reference
  51. van Dongen JJM, Krissansen GW, Wolvers-Tettero ILM, et al. Cytoplasmic expression of the CD3 antigen as a diagnostic marker for immature T-cell malignancies. Blood. 1988; 71:603-612. (Biology).
View All (51) View Less
337190 Rev. 1

Please refer to Support Documents for Quality Certificates

Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described

Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. 

 

Although not required, these products are manufactured in accordance with Good Manufacturing Practices.